Skip to main content

Table 2 Adverse events: weeks 0 through 24

From: Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)

System

Number

Description

Musculoskeletal

31

Arthritis/arthralgia (15), back pain (4), unspecific pain (3) osteopenia/osteoporosis (3), morning stiffness (1), tendovaginosis stenosans (1), plantar fascia pain (1), worsening fibromyalgia (1), tendinitis calcarea (1)

Infection

25

Upper airway infection (18), herpes labialis (2), fungi infection (2), fever (3)

Gastrointestinal

13

Vomiting (4), diarrhea (3), flatulence (1), diabetes mellitus (1), abdominal cramps (1), esophageal reflux (1), aphthous ulcers (1), lip blisters (no herpes proven, 1)

Neuro-psychological

14

Patient falling (4), restless legs (1), neuropathy (1), reduced leg strength (1), fatigue (1), anxiety (1), dysesthesia (1), depression (1), hyperventilation (1), involuntary movements (1), dizziness (1)

Other

7

Leg edema (2), polyp on vocal cord (2, same patient), hypokalemia (1), suspected claudicatio (1), vitamin D deficiency (1),

Dermatological

6

Exanthema (2), hematoma (2), hair loss (1), red eye (1)